Watchlist Sponsored By :
|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Social Networking's 'Naked' Truth
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Geek Squad V. Gizmodo
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Blog You!!!
- Nora Tobin Answers Our Call
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
Glaxo Drug May Help Shrink Metastatic Brain Tumors
Topics:Pharmaceuticals
Companies:GlaxoSmithKline plc
Study results show the new oral drug Tykerb from GlaxoSmithKline, combined with chemotherapy, may shrink metastatic brain tumors.
The data presented Sunday at a breast cancer conference in San Antonio indicate that 20 percent of patients whose cancer had spread to their brain saw their brain tumors cut more than in half, and 37 percent of patients had them shrink 20 percent or more.
Experts say very few drugs have been shown to be able to get at brain metastases in patients with a certain type of advanced breast cancer.
The study, which Glaxo [GSK
Loading...
()
] paid for, was relatively small, and investigators say larger tests are needed.
© 2009 CNBC.com
MORE FROM CNBC








